Drug intelligence / Profile preview

BWH-01

Development stage: Preclinical
Lead developer: Shanghai Argo Biopharmaceutical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

BWH-01 is a small interfering RNA (siRNA) therapeutic candidate currently in preclinical development by Chengdu Xinzhenghe Pharmaceutical Technology (also known as Argo Biopharma). The drug is designed to treat heart disease, utilizing RNA interference to silence specific genetic targets associated with cardiovascular pathology. As part of Argo Biopharma's broader pipeline of siRNA assets, BWH-01 represents an effort to apply oligonucleotide-based modalities to chronic cardiovascular conditions, though its specific molecular target has not been publicly disclosed.

Beyond the preview

Go deeper on BWH-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BWH-01.

Explore the full profile